Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma-Reference-Cited by-同舟云学术

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Published:2024-01 Issue: Volume:196 Page:113457
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

de Miguel-Perez Diego^ORCID,Pickering Edward M.,Malapelle Umberto^ORCID,Grier William^ORCID,Pepe Francesco,Pisapia Pasquale^ORCID,Russo Gianluca^ORCID,Pinto Joseph A.,Russo Alessandro,Troncone Giancarlo,Culligan Melissa J.,Scilla Katherine A.,Mehra Ranee,Mohindra Pranshu,Arrieta Oscar^ORCID,Cardona Andres F.,Del Re Marzia,Sachdeva Ashutosh^ORCID,Hirsch Fred R.,Wolf Andrea,Friedberg Joseph S.,Rolfo Christian^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

2. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification;Sauter;J Thorac Oncol,2022

3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma;Govindan;J Immunother Cancer,2022

4. Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline;Kindler;J Clin Oncol,2018

5. A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint national cancer institute-international association for the study of lung cancer-mesothelioma applied research foundation taskforce;Friedberg;J Thorac Oncol,2019